[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sars-cov-2-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sars-cov-2-infection":533},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,46,80,114,142,171,197,221,245,271,293,326,360,384,411,440,463,490,511],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100641699","cardiovascular-assessment-5-years-after-mis-c-100641699",false,"NCT07659847","Cardiovascular Assessment 5 Years After MIS-C","Cardiovascular Evaluation 5 Years After Multisystem Inflammatory Syndrome in Children (MIS-C)","Inclusion Criteria:\n\n* For the MIS-C group: History of MIS-C diagnosed according to World Health Organization (WHO) criteria\n* For all participants: Written informed consent from a parent or legal guardian and, where applicable, assent\u002Fconsent from participants aged 16 years or older \u002F\n\nExclusion Criteria:\n\nMIS-C group:\n\n1. Known heart disease, including congenital heart disease.\n2. Significant chronic disease affecting growth, development, or daily functioning.\n\nControl group:\n\n1. Elimination diet.\n2. Competitive athletic training.\n3. Known heart disease, including congenital heart disease.\n4. Significant chronic disease affecting growth, development, or daily functioning.",true,"ALL",{"count":19,"type":20},90,"ESTIMATED","OBSERVATIONAL","Multisystem inflammatory syndrome in children (MIS-C) is a severe complication associated with SARS-CoV-2 infection that frequently affects the cardiovascular system. Although acute cardiac abnormalities usually resolve, the long-term cardiovascular consequences of MIS-C remain uncertain. Previous follow-up of this cohort 2 years after MIS-C identified signs of subclinical cardiovascular abnormalities compared with healthy controls.\n\nThis cross-sectional study aims to evaluate cardiovascular health in individuals 5 years after MIS-C. Participants with a history of MIS-C will be compared with age- and sex-matched healthy controls using cardiovascular imaging, vascular assessments, cardiopulmonary exercise testing, and biomarkers of endothelial injury.",[24,25],"Multisystem Inflammatory Syndrome in Children (MIS-C)","SARS-CoV-2 Infection",[27,28,29,30,31,24,32],"Pediatric Inflammatory Multisystem Syndrome (PIMS)","SARS-CoV-2","Endothelial Dysfunction","Cardiovascular Health","Long-Term Outcomes","Arterial Stiffness","RECRUITING","2026-06-15",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":37},"2025-11-22",{"date":41,"type":20},"2027-03-31",{"name":43,"class":44},"Medical University of Warsaw","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":21,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100643130","expression-of-inflammatory-markers-in-the-course-of-acute-respiratory-viral-infections-100643130","NCT07643688","Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections","Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections in Adults Aged 60 Years and Older: a Prospective Observational Study in Primary Case","AIRE-INT","Inclusion Criteria:\n\nGROUP A (Infected-Positive)\n\n* Age ≥60 years.\n* Symptoms compatible with viral respiratory infection (fever, cough, nasal congestion, dyspnea, etc.) between 24h and 72h from symptom onset.\n* Confirmed diagnosis, positive for influenza, RSV, or SARS-CoV-2 by rapid test.\n* Signed informed consent at visit 1.\n\nGROUP B (Non-Infected-Negative. Controls)\n\n* Age ≥60 years.\n* Negative diagnosis for influenza, RSV, or SARS-CoV-2 by rapid test.\n* Signed informed consent at visit 1.\n\nExclusion Criteria:\n\n* Known severe immunosuppression (e.g., transplant recipient, uncontrolled HIV).\n* Chronic immunosuppressive treatment (except low-dose corticosteroids (≤10 mg\u002F3 months)).\n* Participation in another clinical trial within the last 30 days.\n* Inability to comply with the visit schedule.\n* Immunosuppressive drugs.\n* Drugs indicated for treatment.\n* Oncology patients.\n* Terminal patients.\n* Autoimmune diseases associated with alterations in PD-L1.\n* Systemic lupus erythematosus (SLE).\n* Rheumatoid arthritis (RA).\n* Multiple sclerosis (MS).\n* Type 1 diabetes mellitus (T1DM).\n* Sjögren's syndrome.\n* Myasthenia gravis.\n* Autoimmune thyroiditis (Hashimoto's, Graves' disease).","60 Years",{"count":56,"type":20},150,"60 Days","Respiratory viral infections caused by influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 remain major causes of morbidity, hospitalization, and mortality among older adults worldwide. Current antiviral therapies have limited effectiveness and generally require administration within the first 48 hours after symptom onset. Increasing evidence suggests that the programmed death receptor-1\u002Fprogrammed death ligand-1 (PD-1\u002FPD-L1) immune checkpoint pathway plays an important role in the host immune response during acute viral respiratory infections. Upregulation of PD-L1 has been associated with impaired antiviral T-cell activity, immune exhaustion, and disease progression in influenza, RSV, and SARS-CoV-2 infections.\n\nThe AIRE-INT study is a prospective, observational, multicenter, non-interventional study designed to characterize the temporal kinetics of PD-L1 expression and inflammatory biomarkers in adults aged 60 years or older presenting with acute respiratory viral infection.\n\nThe study will be conducted in primary care centers and urgent care facilities within the Barcelonès Nord and Maresme healthcare regions in Catalonia, Spain. A total of 150 participants will be enrolled, including 75 with confirmed viral respiratory infection and 75 controls with negative rapid antigen tests for influenza, RSV, and SARS-CoV-2.\n\nEligible participants must be aged ≥60 years and present within 24 to 72 hours after the onset of respiratory symptoms compatible with acute viral infection, including fever, cough, nasal congestion, or dyspnea. Participants in the infected group must have a positive rapid antigen test for influenza, RSV, or SARS-CoV-2. Control participants must test negative for all three viruses. Written informed consent will be obtained before enrollment.\n\nParticipants with severe immunosuppression, chronic immunosuppressive therapy, active oncologic disease, terminal illness, or autoimmune diseases associated with PD-L1 dysregulation will be excluded.\n\nEach participant will be followed for up to 60 days and will complete two in-person study visits and one follow-up assessment.\n\nVisit 1 will occur between 24 and 72 hours after symptom onset and will include informed consent, collection of demographic and clinical data, assessment of symptoms and medical history, rapid antigen testing, and blood sample collection for PD-L1 and inflammatory biomarker analyses.\n\nVisit 2 will occur between 5 and 9 days after symptom onset and will include repeat clinical assessment and blood sample collection to evaluate temporal changes in PD-L1 expression and inflammatory responses during the acute phase of infection.\n\nVisit 3 will occur between 30 and 60 days after symptom onset and will consist of clinical follow-up through telephone contact and electronic medical record review to assess symptom resolution, complications, hospitalization, intensive care admission, and mortality.\n\nLaboratory analyses will include flow cytometry quantification of PD-L1 expression and evaluation of inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), complete blood count parameters, renal and hepatic function markers, and virus-specific IgG antibodies. Blood samples will be processed according to standardized laboratory procedures at the Hospital Germans Trias i Pujol Microbiology Department.\n\nThe primary objective is to characterize the temporal profile of PD-L1 expression from symptom onset to infection resolution in older adults with influenza, RSV, or SARS-CoV-2 infection.\n\nSecondary objectives include:\n\nDescribing the evolution of inflammatory serum biomarkers and their association with disease severity.\n\nIdentifying biomarkers useful for screening, prognosis, and clinical monitoring.\n\nEstablishing a biological reference framework for future evaluation of PD-L1 inhibitors in respiratory viral infections.\n\nThe primary outcome measure is the level and temporal evolution of PD-L1 expression and inflammatory biomarkers between study visits. Secondary outcomes include hospitalization, intensive care admission, mortality at 60 days, symptom duration, and clinical progression.\n\nStatistical analyses will include descriptive and univariate analyses, longitudinal modeling of biomarker kinetics using locally estimated scatterplot smoothing (LOESS) and nonlinear mixed-effects regression models, and predictive logistic regression models evaluating associations between biomarkers and clinical outcomes.\n\nThe study is expected to provide important information regarding the kinetics of PD-L1 expression and inflammatory responses during acute respiratory viral infections in older adults. The findings may support the development of prognostic biomarkers and future host-directed therapeutic strategies targeting the PD-1\u002FPD-L1 pathway across multiple respiratory viruses.",[60,61,62],"SARS CoV 2 Infection","RSV Infections","Influenza Infection",[28,64,65,66,67,68,69],"Influenza, Human","Respiratory Syncytial Viruses","Observational Study","Programmed Cell Death 1 Receptor","Primary Health Care","Kinetics","NOT_YET_RECRUITING","2026-06-09",{"date":73,"type":37},"2026-06-11",{"date":75,"type":20},"2026-07-01",{"date":77,"type":20},"2027-12",{"name":79,"class":44},"Fabiana Sherine Ganem dos Santos",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100514023","covid-19-transmission-and-morbidity-in-malawi-100514023","NCT05973084","COVID-19 Transmission and Morbidity in Malawi","COVID-TMM","Inclusion Criteria Index Cases\n\n1. Presents with symptoms of COVID-19 and has infection confirmed through RT-PCR or a rapid antigen test;\n2. Aged 5 years to 75 years and plans to live in Blantyre, in the catchment area of the target research health centers for the following 6 months;\n3. Confirmed SARS-CoV-2 infection and share a household with 1 or more individuals of eligible age;\n4. Has not received a SARS-CoV-2 vaccine in the previous 3 months\n5. Willingness to comply with study procedures and visits, and provides informed consent.\n\nHousehold Contacts of the Confirmed SARS-CoV-2 Case\n\n1. Aged 5 years to 75 years and plans to live in Blantyre, in the catchment area of the target research health centers in the following 6 months;\n2. Willingness to comply with study procedures and follow-up visits and provides informed consent.\n3. Has not received a SARS-CoV-2 vaccine in the previous 3 months\n\nVaccinees\n\n1\\) Aged 18 years to 75 years; 2) Willingness to receive the primary regimen of the AZ and\u002For JJ vaccines 2) Not in the other 2 cohorts; 4) Willingness to comply with study procedures and follow-up visits and provides informed consent.\n\n5\\) Has not received a prior dose of a SARS-CoV-2 vaccine\n\nExclusion Criteria Index Cases\n\n1. Conditions that precludes from adherence to the visit schedule;\n2. 50% or more of household members decline to participate.\n3. Pregnancy at the enrollment visit\n4. Long term use of cotrimoxazole prophylaxis\n\nHousehold Contacts of the Confirmed SARS-CoV-2 Case\n\n1. Conditions that preclude adherence to the visit schedule.\n2. Participants with 2 consecutive negative SARS-CoV-2 RT-PCRs will be excluded from visits after M1.\n3. Pregnancy at the enrollment visit\n4. Long term use of cotrimoxazole prophylaxis\n\nVaccinees\n\n1. Conditions that preclude adherence to the visit schedule.\n2. Pregnancy at the enrollment visit\n3. Long term use of cotrimoxazole prophylaxis","5 Years","75 Years",{"count":90,"type":20},1500,"SARS-CoV-2 transmission was expected to have a devastating impact in sub-Saharan African countries. Instead, morbidity and mortality rates in nearly the whole region are an order of magnitude lower than in Europe and the Americas. To identify what is different requires a better understanding of the underlying immunological substrate of the population, and how these factors affect susceptibility to infection, progression of symptoms, transmission, and responses to SARS-CoV-2 vaccination.\n\nStudy objectives\n\n1. Determine the risk and predictors of infection and disease among contacts of SARS-CoV-2 infection subjects in Malawi\n2. Determine whether innate immune responses lower the risk of SARS-CoV-2 infection and disease, and acquisition and duration of vaccine responses.\n3. Assess whether alterations in innate immune responses relevant to SARS-CoV-2 are associated with malaria or intestinal parasite infections.\n4. Assess the acquisition and longevity of antibodies (Ab) and cellular adaptive responses elicited by SARS-CoV-2 infection and vaccination.\n5. Assess whether malaria and intestinal parasite infections, chronic\u002Fmild undernutrition, and anemia mediate alterations in Ab and other adaptive cellular responses to SARS-CoV-2 through innate immune responses or a different unknown mechanism.",[60,93],"SARS CoV 2 Vaccination",[95,96,97,98,99,100,101,102,103],"Natural infection","Immune phenotypes","Innate immunity","SARS CoV 2 adaptive immunity","SARS CoV 2 antibody response","Vacinees","Household contacts","Malawi","Sub Saharan Africa","2026-05-26",{"date":106,"type":37},"2026-05-28",{"date":108,"type":37},"2023-01-17",{"date":110,"type":20},"2028-03",{"name":112,"class":44},"Boston University",2,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":16,"sex":17,"minAge":122,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":125,"phases":126,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":140,"locationsCount":113},"100523752","evaluation-of-concordance-between-exhaled-air-test-ebam-cov-and-rt-pcr-to-detect-sars-cov-2-100523752","NCT06099795","Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2","Evaluation of Concordance Between an Innovative Test on Exhaled Air (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2 in Symptomatic Patients or Closed Contacts","eBAM_CoV","Inclusion Criteria:\n\n* Adult male or female patients over 18 years of age (≥)\n* Suspected of being infected with COVID-19 (symptomatic or contact case) and consulting for RT-PCR screening.\n\nExclusion Criteria:\n\n* Inability to understand the procedures to use the device\n* Patient participating in an another interventional study\n* Patient in exclusion period determined by another study\n* Patient under court protection or guardianship\n* Patient\u002Ftrusted person\u002Flegal representative\u002Ffamily member for whom it is impossible to give informed information.\n* Pregnant, parturient or breast-feeding patient","18 Years",{"count":124,"type":20},250,"INTERVENTIONAL",[127],"NA","During the COVID-19 pandemic, testing primarily relied on the use of nasopharyngeal swabs to detect the SARS-CoV-2 virus, responsible for the disease. However, this technique has several limitations, including the variable quality of swabs, its invasive nature, and arbitrariness in the choice of the number of cycles. Furthermore, it does not allow for the detection of viral proteins.\n\nTo overcome these limitations, researchers developed the eBAM-CoV test, patented for the detection of viral proteins in the exhaled air of COVID-19 patients. This portable device provides an immediate assessment of the \"viral load\" with both quantitative and qualitative results, showing promise for early virus detection.\n\nThe researchers hypothesize that the eBAM-CoV test is likely to exhibit a satisfactory concordance with the reference RT-PCR test in the detection of COVID-19, especially among symptomatic patients or closed contacts.",[25,130,131],"COVID-19","Coronavirus",[133],"Diagnostic Test Kits","2026-05-22",{"date":136,"type":37},"2026-05-27",{"date":138,"type":37},"2025-01-01",{"date":77,"type":20},{"name":141,"class":44},"Centre Hospitalier Universitaire de Nīmes",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":122,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":125,"phases":152,"briefSummary":154,"conditions":155,"keywords":159,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":170},"100564600","phase-3-randomized-double-blind-placebo-controlled-trial-evaluating-baricitinib-on-persistent-neurologic-and-cardiopulmonary-symptoms-of-long-covid-100564600","NCT06631287","Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID","Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (REVERSE-LC)","REVERSE-LC","INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this investigation, an individual must meet all of the following criteria:\n\nCohort #1 (n=500):\n\n1. Evidence of personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study and was willing and able to consent to participation.\n2. Age ≥18 years old.\n3. Documented SARS-CoV-2 infection 6 or more months prior to screening, confirmed with acceptable documentation that includes (at minimum) their name, the date the test was taken (must be after January 2020), and details specifying that the positive test was for SARS-CoV-2 infection.\n4. Clinical evidence of Long COVID, as confirmed by the investigator's assessment:\n\n   a. At least one symptom (listed below) that is new or worsened since the time of SARS-CoV-2 infection, not known to be attributable to another cause upon assessment by the study clinicians (MD, DO, NP, PA, RN, or equivalent).\n\n   i. Systemic symptoms (e.g., fatigue, chills, post-exertional malaise), neurocognitive symptoms (e.g., trouble with memory\u002Fconcentration (\"brain fog\"), headache, dysautonomia\u002Fpostural orthostatic tachycardia syndrome, dizziness, unsteadiness, neuropathy, sleep disturbance), cardiopulmonary symptoms (e.g., chest pain, palpitations, shortness of breath, cough, fainting spells), musculoskeletal symptoms (e.g., muscle aches, joint pain), gastrointestinal symptoms (e.g., nausea, diarrhea). Although other symptoms (e.g., skin rash, hair loss, mental health symptoms, trouble with smell\u002Ftaste, genitourinary symptoms) will be recorded and tracked, at least one core symptoms listed above must be present.\n\n   b. Symptoms must be present for at least 6 months prior to screening. Symptoms that wax and wane must have been initially present at least 6 months prior to screening.\n\n   c. Symptoms must be reported to have an impact on quality of life and\u002For everyday functioning and to be at least somewhat bothersome.\n\n   d. Cognitive impairment present defined by having at least 20% positive items (answered subjectively worse or much worse) on the 41-item modified ECog questionnaire.\n\nCohort #2 (n=50):\n\n1. Evidence of personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study and was willing and able to consent to participation.\n2. Age ≥18 years old.\n3. Clinical diagnosis of COVID infection between January 2020 and September 1, 2021 (i.e., before home tests were widely available).\n\n   a. Clinical Criteria (Based on Council of State and Territorial Epidemiologists Standardized Surveillance Case Definition for COVID-19): i. At least two of the following symptoms: Fever (measured or subjective), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s).\n\n   -OR- ii. At least one of the following symptoms: Cough, shortness of breath, or difficulty breathing.\n\n   -OR- iii. Severe respiratory illness with at least one of the following: clinical or radiographic evidence of pneumonia or Acute Respiratory Distress Syndrome (ARDS).\n\n   -AND- iv. No alternate more likely diagnosis\n4. Clinical evidence of Long COVID, as confirmed by the clinician's assessment:\n\n   a. At least one symptom (listed below) that is new or worsened since the time of SARS-CoV-2 infection, not known to be attributable to another cause upon assessment by the study clinicians (MD, DO, NP, PA, RN, or equivalent).\n\n   i. Systemic symptoms (e.g., fatigue, chills, post-exertional malaise), neurocognitive symptoms (e.g., trouble with memory\u002Fconcentration (\"brain fog\"), headache, dysautonomia\u002Fpostural orthostatic tachycardia syndrome, dizziness, unsteadiness, neuropathy, sleep disturbance), cardiopulmonary symptoms (e.g., chest pain, palpitations, shortness of breath, cough, fainting spells), musculoskeletal symptoms (e.g., muscle aches, joint pain), gastrointestinal symptoms (e.g., nausea, diarrhea). Although other symptoms (e.g., skin rash, hair loss, mental health symptoms, trouble with smell\u002Ftaste, genitourinary symptoms) will be recorded and tracked, at least one core symptoms listed above must be present.\n\n   b. Symptoms must be present for at least 6 months prior to screening. Symptoms that wax and wane must have been initially present at least 6 months prior to screening.\n\n   c. Symptoms must be reported to have an impact on quality of life and\u002For everyday functioning and to be at least somewhat bothersome.\n\n   d. Cognitive impairment present defined by having at least 20% positive items (answered subjectively worse or much worse) on the 41-item modified ECog questionnaire.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this investigation:\n\n1. Qualifying Long COVID symptoms cannot be explained by an infection-associated chronic condition diagnosed prior to the onset of Long COVID (e.g., ME\u002FCFS or other infection-associated chronic condition).\n2. Pre-existing cognitive impairment not exacerbated by COVID-19, including but not limited to syphilis, as determined by study clinicians (MD, DO, NP, PA, RN, or equivalent), which may include a review of participant's history and medical records.\n3. Severe cognitive, physical, or psychological disability preventing participation in the study, as determined by the investigator.\n4. Moderate or High risk of suicidality, as determined by the modified Columbia Suicide Severity Rating Scale (mC-SSRS).\n5. History of a major adverse cardiovascular event (MACE) within the 3 months prior to enrollment.\n6. Current use of baricitinib or other disease-modifying antirheumatic drug (DMARDs); however, DMARDs with minimal immunomodulatory effects (hydroxychloroquine, i.e., Plaquenil, steroids used for less than 2 weeks, minocycline), are not exclusionary.\n7. Known prior allergic reactions to components of the baricitinib.\n8. Previously randomized in this study or in the last 30 days have been in another study investigating baricitinib.\n9. Positive SARS-CoV-2 NAAT or rapid Antigen test in the 14 days prior to screening.\n10. Venous thromboembolism in the past 6 months prior to screening or felt to be at increased risk of thrombosis by the investigator.\n11. Malignancy or lymphoproliferative disorder not in remission for at least 5 years. Local non-melanoma skin cancers that are definitively managed are not exclusionary.\n12. Previous admission to an ICU for treatment of acute COVID-19 infection.\n13. Estimated glomerular filtration rate of \\\u003C 30 mL\u002Fmin\u002F1.73m2, as calculated using the CKD-EPI 2021 equation.\n14. Absolute Neutrophil Count (ANC) \\\u003C1000 cells\u002Fmm3, confirmed on repeat testing.\n15. Absolute Leukocyte Count (ALC) \\\u003C100 cells\u002Fmm3.\n16. Evidence of severe liver disease at the time of screening, defined as Bilirubin \\> 1.5 X ULN or AST or ALT \\> 2x ULN.\n17. Alkaline Phosphatase (ALP) ≥ 3x ULN.\n18. Creatine Phosphokinase (CPK) ≥ 3x ULN.\n19. Hemoglobin (HgB) \\\u003C 8 g\u002FdL, confirmed on repeat testing.\n20. Platelets \\\u003C100,000 cells\u002Fmm3, confirmed on repeat testing.\n21. Platelets \\>500,000 cells\u002Fmm3, confirmed on repeat testing.\n22. Total fasting cholesterol ≥ 280 mg\u002FdL, confirmed on repeat testing.\n23. Fasting LDL ≥ 180 mg\u002FdL, confirmed on repeat testing.\n24. Positive Hepatitis B surface antigen or Hepatitis B core antibody. Note: Individuals with a positive Hepatitis B core antibody will be excluded even in the presence of a positive Hepatitis B surface antibody due to the risk of reactivation.\n25. Positive for Hepatitis C at the time of Screening. Note: treated or cleared Hepatitis C is not exclusionary.\n26. Symptomatic herpes zoster infection (i.e., visible herpetic skin lesions of Zoster) within 3 months prior to study screening, or any history of disseminated\u002Fcomplicated herpes zoster or herpes simplex infection (e.g., VZV encephalitis).\n27. History of untreated latent tuberculosis infection (diagnosed with QuantiFERON-TB Gold Plus testing) or active tuberculosis whether treated or untreated. Note: those with a positive PPD who have a history of BCG vaccine and a negative QuantiFERON-TB Gold Plus test will remain eligible).\n28. History of current or recent (\\\u003C 30 days from screening) sepsis or clinically significant viral, bacterial, fungal, or parasitic infection, according to the determination of the investigator.\n29. Participants with HIV will be excluded if they have been on ART \\\u003C1 year, have a CD4+ T cell count \\\u003C500 cells\u002Fml (confirmed on repeat), or have two consecutive HIV plasma RNA viral load \\> 48 copies\u002FmL within 1 year of study screening, including requiring the most recent within 3 months of screening. Blips (VL \\> 48 copies\u002FmL but \\\u003C 200 copies\u002FmL) are permitted if preceded and followed by values below the assay limit of quantification.\n30. Immunocompromised as defined by NIH COVID-19 guidelines (see Appendix) and, in the opinion of the investigator, at an unacceptable risk for participating in the study.\n31. Treatment with another investigational drug or device as part of an interventional study within 30 days of study screening.\n32. In the opinion of the investigator, unable to reliably follow-up for the duration of the study and\u002For are unable to follow study restrictions\u002Fprocedures.\n33. Persons of childbearing potential under age 55 who are unwilling or unable to abstain from sex or to use at least one acceptable method of contraception from the time of screening though at least 28 days after the end of the study intervention period. Note: Acceptable methods include barrier contraceptives (condoms or diaphragm) with spermicide, intrauterine devices (IUDs), other contraceptives, oral contraceptive pills, and surgical sterilization. Participants unwilling to be counseled about risks related to pregnancy or breastfeeding.\n34. Currently pregnant or breastfeeding or planning to become pregnant or breastfeed during the course of the study.\n35. Participants actively breastfeeding, who are unwilling to stop breastfeeding for the duration of the trial.\n36. Currently incarcerated\n\nNOTE RE: History of major adverse cardiovascular event (MACE) or traditional risk factors including smoking. For REVERSE-LC, MACE is defined as acute myocardial infarction and stroke. The study team will discuss the risks and benefits of baricitinib and CV events with the participant prior to study entry.\n\nNOTE RE: EBV\u002FCMV Seropositivity - The investigators will not exclude participants based on EBV or CMV seropositivity. The investigators already know that serologic evidence suggesting recent EBV reactivation is associated with Long COVID fatigue and high level EBV responses are associated with neurocognitive Long COVID, but that EBV viremia and IgM is rare. The investigators believe there is equipoise with regard to the potential effects of baricitinib on EBV - it is as likely that inflammation drives EBV reactivation, just as EBV can drive inflammation. For this reason, the investigators think this is best studied as a biological factor correlated with outcomes and that the investigators should not deliberately include or exclude people based on this. CMV seropositivity is associated with improved Long COVID outcomes. Results are not required for screening.",{"count":151,"type":20},550,[153],"PHASE3","The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.",[156,157,158,130],"Long COVID","Sars-CoV-2 Infection","Coronavirus Infections",[130,160,156],"Long COVID Drug Treatment","2026-05-07",{"date":163,"type":37},"2026-05-11",{"date":165,"type":37},"2024-10-21",{"date":167,"type":20},"2027-07-01",{"name":169,"class":44},"Wes Ely",17,{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":16,"sex":17,"minAge":179,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":125,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":45},"100466918","exercise-in-child-health-100466918","NCT05359991","Exercise in Child Health","Revamping Exercise Assessments in Child Health (Project REACH)","Project REACH","Inclusion Criteria:\n\nSickle Cell Disease\n\n* Tanner 1-5, corresponding approximately to ages 10-17 y\u002Fo\n* SCD diagnosis including all relevant genotypes\n* Determined to be in relatively good health as a patient with SCD with no complications from SCD that would render participation the study unadvisable\n* No evidence of other disease or disability that would impair participation in PA\n* Physician permission to perform CPET\n* BMI within the average range for age and condition\n\nCystic Fibrosis\n\n* Confirmed diagnosis of CF based on either two CF-causing mutations and\u002For a sweat chloride concentration of \\> 60 mmol\u002Fl after a positive newborn screening test or on two separate occasions\n* Tanner 1-5 corresponding approximately to ages 10-17 y\u002Fo as documented by a licensed independent provider at screening, or by a validated self-assessment tool\n* Determined to be in relatively good health as a patient with CF with no complications from CF that would render participation the study unadvisable as determined by a physician. Examples include history of submassive or massive hemoptysis or moderate to severe pulmonary hypertension.\n* BMI in the average range for age and condition\n* No evidence of other disease or disability that would impair participation in PA\n\nComparison (Healthy control)\n\n* Tanner 1-5 corresponding approximately to ages 10-17 y\u002Fo\n* Determined to be in good health by pre-participation history and physical examination performed by primary care providers or PERC staff\n* BMI and PA participation (by history) in the average range for age\n* No evidence of disease or disability that would impair participation in PA\n\nComparison (SARS-CoV-2)\n\n* Tanner 1-5 corresponding approximately to ages 10-17 y\u002Fo\n* Documented SARS-CoV-2 infection\n* Capable of doing exercise as determined by primary care providers or PERC a medical officer\n\nExclusion Criteria:\n\nSickle Cell Disease Treatment for substance or alcohol abuse\n\n* Requiring chronic monthly transfusions\n* Other conditions that preclude exercise such as neuromotor disease, heart disease, or any other condition that would prevent a child from participating in PA\n\nCystic Fibrosis Treatment for substance or alcohol abuse\n\n* Other conditions that preclude exercise (such as neuromotor disease, heart disease, or any other condition that would prevent a child from participating in PA)\n* FEV1 \\\u003C 40% predicted based on Global Lung Index equations\n* Current infection with Burkholderia cenocepacia or Mycobacterium abscessus\n\nComparison (Healthy control) Treatment for substance or alcohol abuse or chronic medication use • Determination by PERC staff of unsuitability for exercise\n\nComparison (SARS-CoV-2) Treatment for substance or alcohol abuse or chronic medication use\n\n• Determination by PERC staff of unsuitability for exercise","10 Years","17 Years",{"count":182,"type":20},240,[127],"This study is a cooperative investigation funded by the NIH. The project is a collaboration among three major NIH Clinical Translational Science Awardees: 1) UCI (lead site with its affiliate CHOC), 2) Northwestern University (with its affiliate Lurie Children's Hospital), and 3) USC (with its affiliate Children's Hospital of Los Angeles).\n\nThere is an increasing number of children who, through medical advances, now survive diseases and conditions that were once fatal, but which remain chronic and debilitating. A major challenge to improve both the immediate and long term care and health of such children has been the gap in our understanding of how to assess the biological effects of exercise. Like otherwise healthy children, children with chronic diseases and disabilities want to be physically active. The challenge is to determine what constitutes safe and beneficial level of physical activity when the underlying disease or condition \\[e.g., cystic fibrosis (CF) or sickle cell disease (SCD)\\] imposes physiological constraints on exercise that are not present in otherwise healthy children. Current exercise testing protocols were based on studies of athletes and high performing healthy individuals and were designed to test limits of performance at very high-intensity, unphysiological, maximal effort. These approaches are not optimal for children and adolescents with disease and disability. This project (REACH-Revamping Exercise Assessment in Child Health) is designed to address this gap. Cohorts of children will be identified with two major genetic diseases (CF and SCD) and measure exercise responses annually as they progress from early puberty to mid or late puberty over a 3-4year period. In addition, in the light of the pandemic, a group of children will be added who were affected by SARS-CoV-2 and investigate their responses to exercise. SARS-CoV-2 has similar long-term symptoms than CF and SCD have. Novel approaches to assessing physiological responses to exercise using advanced data analytics will be examined in relation to metrics of habitual physical activity, circulating biomarkers of inflammation and growth, leukocyte gene expression, and the impact of the underlying CF, SCD or SARS-CoV-2 condition. The data from this study will help to develop a toolkit of innovative metrics for exercise testing that will be made available to the research and clinical community.",[186,187,60],"Cystic Fibrosis","Sickle Cell Disease","2026-03-19",{"date":190,"type":37},"2026-03-24",{"date":192,"type":37},"2020-11-12",{"date":194,"type":20},"2026-06-30",{"name":196,"class":44},"University of California, Irvine",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":204,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":125,"phases":208,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":113},"100450097","phase-1-t-cell-therapy-opposing-novel-covid-19-infection-in-immunocompromised-patients-100450097","NCT05141058","T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients","TONI","Inclusion Criteria:\n\nParticipant Inclusion Criteria for CST Infusion:\n\n1. For recipient of CSTs derived from an HSCT donor under Arm A:\n\n   a. Patients aged ≥18 years and \\\u003C80 years who were recipients of prior myeloablative or non-myeloablative allogeneic HSCT using either bone marrow or peripheral blood stem cells or single or double cord blood ≥28 days and \\\u003C4 months ago who are at risk of SARS-CoV-2 infection.\n2. For recipient of CSTs derived from an HSCT donor under Arms B and C:\n\n   a. Patients aged ≥2 years and \\\u003C18 years who were recipients of prior myeloablative or non-myeloablative allogeneic HSCT using either bone marrow or peripheral blood stem cells or single or double cord blood ≥28 days and \\\u003C4 months ago who are at risk of SARS-CoV-2 infection.\n3. Have evidence of primary engraftment following HSCT (defined by ANC ≥500\u002Fmm3 for three consecutive measurements on different days, respectively)\n4. Participants receiving calcineurin inhibitors for treatment of GVHD, or for other reasons, should not have any dosage changes within 7 days prior to infusion\\*\\*\n\n   a. For patients receiving steroids, dosage must have been tapered to \\\u003C0.5 mg\u002Fkg\u002Fday of prednisone (or equivalent) at least 7 days prior to infusion.\n5. Karnofsky\u002FLansky score \\>70.\n6. ≥2 years to \\\u003C80 years of age at enrollment.\n7. Absolute neutrophil count (ANC) ≥500\u002Ful.\n8. Hemoglobin ≥8.0g\u002Fdl (level can be achieved with transfusion).\n9. Platelets ≥20 K\u002Ful (level can be achieved with transfusion)\\*.\n10. Bilirubin ≤2x upper limit normal.\n11. Aspartate transaminase (AST) ≤2.5x upper limit of normal.\n12. Alanine transaminase (ALT) ≤2.5x upper limit of normal.\n13. Estimated GFR \\>60mL\u002Fmin\u002F1.73m2 (calculated per institutional standards).\n14. Pulse oximetry of ≥92% on room air for at least 7 days prior to infusion.\n15. Age appropriate mean arterial pressure without the use of vasopressors.\n16. Negative pregnancy test in female participant of childbearing potential.\n17. Male and female participants of childbearing potential must use highly effective birth control measures or practice abstinence for a minimum of 6 months after receiving study therapy\n18. Written informed consent and\u002For signed assent line from participant, parent or guardian.\n\nDonor Inclusion Criteria:\n\n1. Donors for allogeneic (i.e. HLA matched or mismatched related or unrelated) stem cell transplants who have fulfilled eligibility as per FDA regulations outlined in 21 Code of Federal Regulations (CFR) 1271 subpart C. This includes that donors have been deemed in good health by donor physician based on physical examination and laboratory testing. If a donor has been chosen for the transplant based on urgent medical need that same donor will also be used for CST generation provided that there are no new reasons for ineligibility since the stem cell collection.\n2. Donor or guardian of pediatric donor capable of providing informed consent.\n3. 2 to 80 years of age.\n4. Female donors of childbearing potential must have a negative pregnancy test.\n\nExclusion Criteria:\n\nParticipants Exclusion Criteria for CST Infusion:\n\n1. Participants receiving biological or immunosuppressive monoclonal antibodies targeting T cells within 28 days prior to CST infusion, including ATG, Alemtuzumab, Basiliximab, Tociluzimab, Brentuximab, or other medications under this category as determined by the investigators.\n\n   a. If alemtuzumab has been received within 6 weeks prior to CST infusion, plasma levels should be obtained to ensure drug clearance (≤0.16 pg\u002Fml).\n2. Participants who have received donor lymphocyte infusion (DLI), chimeric antigen receptor T cell infusion, or other experimental cellular therapies within 28 days prior to CST infusion.\n3. Participants who have received ruxolitinib or other JAK inhibitors within 7 days prior to CST infusion.\n4. Participants with uncontrolled or progressing infections or active infections causing fever (temperature ≥38.1°C). Uncontrolled infections are defined as bacterial, fungal, or viral infections (including HIV and Hepatitis B and C) with either clinical signs of worsening despite standard therapy that may be attributed to the uncontrolled infection. Progressing infection is defined as hemodynamic instability, worsening physical signs, or radiographic findings attributable to infection.\n\n   1. For bacterial infections, participants must be receiving definitive therapy and have no signs of progressing infection within 7 days prior to CST infusion.\n   2. For fungal infections, participants must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection within 7 days prior to CST infusion.\n5. Participants with unexplained fever (temperature ≥38.1°C) within 7 days prior to CST infusion.\n6. Participants with evidence of active SARS-CoV-2 infection based on SARS-CoV-2 RT-PCR positivity.\n7. Participants with hypotension (mean arterial pressure \\\u003C50mmHg in participants \\\u003C5 years of age, \\\u003C55 mmHg in participants ≥5 and \\\u003C14 years of age or \\\u003C60 mmHg in participants ≥14 years of age).\n8. Participants with pulse pressure \\>40 mmHg.\n9. Participants with respiratory rate \\>20 breaths per minute.\n10. Participants with heart rate ≥140 beats per minute.\n11. Participants with uncontrolled hypertension as defined by systolic blood pressure \\>99th percentile for age (participants \\\u003C18 years), and systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg (participants ≥18 years).\n12. Participants with metabolic instability.\n13. Pediatric participants with modified Ross heart failure Class II disease and adult participants with NYHA Class II disease.\n14. Participants with advanced pulmonary disease as defined by requirement for supplemental oxygen or positive pressure ventilation due to pulmonary disease. (This includes participants with active interstitial lung disease (ILD)\u002Fpneumonitis, advanced pulmonary disease, a history of ILD\u002Fpneumonitis requiring treatment with systemic steroids or a baseline oxygen requirement).\n15. Participants with neurological or psychiatric disorders that would, in the opinion of the investigators, place them at increased risk of harm, impact the investigator's abilities to screen for adverse events in the subject, or impair the subject's ability to provide informed consent.\n16. Participants receiving checkpoint inhibitors within the previous 3 months prior to CST infusion, including nivolumimab, pembroluzimab, or other related medications.\n17. Participants with proven or suspected MIS (in both adults and children) based on the CDC definition and investigator judgement.\n18. Participants who are breastfeeding.\n19. Participants who have received live vaccines within 30 days, or any SARS-CoV-2 vaccine in the past 28 days prior to enrollment.\n20. Participants with any other unrelated medical conditions that would impact the participant's safety in the opinions of the investigators.\n21. Participants anticipated to need a blood transfusion within 48 hours of CST infusion.\n22. Participants unwilling to utilize effective contraception during the study period (if applicable)\n\nDonor Exclusion Criteria:\n\n1. Donation of cells would pose a physical or psychological risk to the donor.\n2. Prior or current complicated course of COVID-19, including but not limited to MIS, CRS, or thromboembolic complications based on investigator judgement.","2 Years","80 Years",{"count":207,"type":20},24,[209],"PHASE1","This is an open label, phase I dose-escalation study to evaluate the safety of coronavirus-specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in immunocompromised patients following hematopoietic stem cell transplantation (HSCT).\n\nParticipants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \\\u003C4 months after HSCT).\n\nIn this dose escalation trial, three doses (1x107\u002Fm2, 2x107\u002Fm2, and 4x107\u002Fm2) will be tested for safety, with study arms for adult (≥18 years of age and \\\u003C80 years) HSCT recipients (Arm A) and two arms for pediatric (≥12 years of age and \\\u003C18 years; ≥2 years and \\\u003C12 years) HSCT recipients (Arm B and Arm C, respectively), and defined dose escalations in each study arm. The study agent will be assessed for safety (stopping rules defined) and antiviral activity.",[25],"2026-03-11",{"date":214,"type":37},"2026-03-12",{"date":216,"type":37},"2021-10-19",{"date":218,"type":20},"2029-12-15",{"name":220,"class":44},"Children's National Research Institute",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":204,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":125,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":4},"100626036","clinical-validation-of-an-at-home-flu-ab-and-covid-19-rapid-test-100626036","NCT07430410","Clinical Validation of an At-Home Flu A\u002FB and COVID-19 Rapid Test","Human Factors and Clinical Validation of the CorDx Tyfast Flu A\u002FB & COVID-19 At Home Multiplex Rapid Test Using Anterior Nares Nasal Samples for Over-The-Counter (OTC) Use","Inclusion Criteria:\n\n1. Written informed consent obtained prior to study enrollment.\n2. Male or female aged 2 years or older.\n3. Subjects were tested with a Food Drug and Administration (FDA) cleared molecular assay no more than 2 days prior to the study visit.\n4. Subject, aged 2 years or older, is currently exhibiting one or more symptoms associated with COVID-19 or influenza such as, but not limited to, fever, chills, cough, shortness of breath or difficulty breathing, fatigue, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea and must present within 5 days of symptom onset. Subject must still be exhibiting symptoms on the day of sample collection.\n\nExclusion Criteria:\n\n1. Subject who is 18 years of age (or the state's legal age of majority) or older and does not understand or is not able and willing to sign the study informed consent.\n2. Subject has had seasonal influenza vaccine within the past 5 days.\n3. Subject is not able to tolerate sample collection, or is not willing to contribute the required swab samples for testing or complete the study procedures.\n4. Subject is currently undergoing antiviral treatment such as baloxavir marboxil (trade name Xofluza®), oseltamivir (Tamiflu®), zanamivir (Relenza®), and peramivir (Rapivab®).\n5. Subjects currently undergoing treatment and\u002For within the past thirty (30) days with prescription medication to treat novel Coronavirus SARS-CoV-2 infection, which may include but is not limited to Remdesivir (Veklury), Paxlovid, molnupiravir or receiving convalescent plasma therapy for SARS-CoV-2.\n6. Subjects who have had a nasal wash or aspirate as part of their standard of care treatment on day of study visit prior to the study sample collection.\n7. Subjects who have had recent craniofacial injury or surgery, including to correct deviation of the nasal septum, within the previous six (6) months.",{"count":229,"type":20},200,[127],"The study's primary objective is to evaluate the performance of the CorDx Tyfast Flu A\u002FB \\& COVID-19 At-Home Test for detecting SARS-CoV-2, Influenza A, and B in nasal samples collected by lay users, compared to 510(k)-cleared RT-PCR tests. Secondary objectives are to assess usability and instruction comprehension and reproducibility with untrained operators at Clinical Laboratory Improvement Amendments (CLIA)-waived sites.",[25,233,234],"Influenza A","Influenza B","2026-02-23",{"date":237,"type":37},"2026-02-25",{"date":239,"type":20},"2026-02-12",{"date":241,"type":20},"2027-02-12",{"name":243,"class":244},"CorDx, Inc.","INDUSTRY",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":122,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":125,"phases":254,"briefSummary":256,"conditions":257,"keywords":261,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":45},"100607544","phase-2-effect-of-2-hoba-in-persistent-immune-activation-in-long-covid-pots-100607544","NCT07189936","Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS","Mechanism of Isolevuglandin-Protein Adduct Formation in Persistent Immune Activation in Long COVID POTS","Inclusion Criteria:\n\nAll participants should meet diagnostic criteria for Long COVID and POTS and as outlined below:\n\nLong COVID (LC) is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection.\n\nPOTS: the presence of chronic symptoms lasting more than 3 months, along with orthostatic tachycardia (a HR increase over 30 bpm upon standing or exceeding 120 bpm without orthostatic hypotension) within 10 minutes upon standing or 75-degree head up tilt.\n\nFor patients aged 18 and 21, an increase of more than 40 bpm or a standing HR over 130 bpm will be required for inclusion in the study.\n\n2 Patients need confirmation of POTS diagnosis based on orthostatic vital signs obtained prior to enrollment in the study.\n\nSARS-CoV-2 infection 3 or more months prior identified by the follow signs:\n\nA. Meets the clinical OR epidemiological criteria.\n\n1. Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness\u002Ffatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia.\n2. Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Presents with acute respiratory infection with history of fever or measured fever of ≥ 38°C; and cough; with onset within the last 10 days; and who requires hospitalization); or C. Presents with no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 antigen-Rapid Diagnostic Test.\n\nD. A person with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or E. Meeting clinical criteria AND\u002FOR epidemiological criteria (See A). With a positive professional use or self-test, SARS-CoV-2 Antigen-Rapid Diagnostic Test.\n\nF. Documented by health care provider in clinical note or encounter.\n\nExclusion Criteria:\n\n1. Known active acute SARS-Cov-2 infection (4 weeks from onset)\n2. Moderate or severe immunocompromised patients,\n3. Known history of cardiovascular disease (atrioventricular block (AV block), myocardial infarction, angina, heart failure, pacemaker, stroke, transient ischemic attack within 6 months before enrollment),\n4. Uncontrolled hypertension (BP\\>140\u002F90 despite appropriate treatment);\n5. Type 1 or type 2 diabetes mellitus;\n6. Impaired hepatic function (AST or ALT greater than 1.5x the upper limit of normal or with total bilirubin ≥1.5mg\u002Fdl),\n7. Impaired renal function test (eGFR\\\u003C60 mL\u002Fmin\u002F1.73m2),\n8. Anemia (hemoglobin \\\u003C10 g\u002Fdl),\n9. Pregnant or breastfeeding women,\n10. Known history of autoimmune disease, steroid use or other immunotherapies,\n11. Inability to provide informed consent.\n\nWe will also exclude individuals with known allergy sensitivity to components of the study medication, known contraindication to the study interventions, use of central acetylcholinesterase inhibitors (e.g., pyridostigmine, donezepil), aspirin allergy because salicylic acid is a metabolite of 2-HOBA; use of monoamine oxidase inhibitors (MAO-I) because of some inhibition of MAO-A is present in the anticipated therapeutic range of 2-HOBA.\n\n\\-",{"count":253,"type":20},50,[255],"PHASE2","Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID.\n\nLong COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS) symptoms include fatigue, exercise intolerance, orthostatic intolerance, syncope, and heightened orthostatic tachycardia.\n\nResearch has found that decreased parasympathetic activity in LCPOTS increases the production of highly immunogenic neoantigens Isolevuglandins (IsoLG-adducts). IsoLG-adducts induce formation of circulating monocyte\u002FT cell complexes(doublets) leading to the persistent and unresolved immune response that continues after the initial infection.\n\nThe purpose of the this research, is to study the effects of 2-hydroxybenzylamine (2-HOBA), an Iso-LG-adduct scavenger, its effects in immune markers and compare it with Placebo",[258,259,60,260],"Post-Acute COVID-19 Syndrome","Postural Tachycardia Syndrome (POTS)","Long COVID19",[156],"2026-01-21",{"date":264,"type":37},"2026-01-22",{"date":266,"type":37},"2025-12-18",{"date":268,"type":20},"2029-06-30",{"name":270,"class":44},"Vanderbilt University Medical Center",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":16,"sex":17,"minAge":122,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":125,"phases":279,"briefSummary":280,"conditions":281,"keywords":283,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":45},"100471617","cardiovascular-autonomic-and-immune-mechanism-of-post-covid-19-tachycardia-syndrome-100471617","NCT05421208","Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome","Inclusion Criteria:\n\n* Prior RT-PCR-confirmed COVID-19 infection.\n* Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (\\>30 bpm) and chronic (\\>3 months) pre-syncopal symptoms.\n\nExclusion criteria:\n\n* Heart Disease: Myocardial Infarction, angina, heart failure\n* History of stroke, or transient ischemic attack\n* Undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries)\n* Uncontrolled hypertension defined as persistent blood pressure \\>140\u002F90.\n* Post-menopausal women.\n* Diabetes Mellitus Type 1 or Type 2. ,\n* Impaired Hepatic function\n* Impaired renal function test (eGFR\\\u003C60 mL\u002Fmin\u002F1.73m2).\n* Ongoing substance abuse.\n* Mental conditions rendering a subject unable to understand the nature, scope and possible consequences of the study.\n* History of seizures.\n* Chronic use of steroids, NSAIDs.\n* On biologics such as anti-IL6 (omalizumab) and anti-TNF-alpha drugs\n* Pregnancy or breastfeeding",{"count":278,"type":20},60,[127],"The term post-acute COVID-19 syndrome or Long COVID is a disabling syndrome that persists beyond the 3-month convalescence period after COVID-19 infections.\n\nThis syndrome affects mostly women (\\~80%), present with chronic tachycardia and Orthostatic intolerance symptoms without any identifiable cause. In addition, non-specific symptoms such as fatigue, headache, and \"brain fog\", commonly described in POTS patients are also present in this novel condition, recently named post-COVID-19 tachycardia syndrome, POTS variant.\n\nReduced Vagal activity and unresolved inflammation is post-COVID-19 POTS is hypothesized as the cause of Long COVID",[282,259,156,60],"Post-acute COVID-19 Syndrome",[284],"SARS-CoV-2 infection","2026-01-15",{"date":287,"type":37},"2026-01-20",{"date":289,"type":37},"2022-06-01",{"date":291,"type":20},"2027-06-30",{"name":270,"class":44},{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":301,"minAge":122,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":305,"conditions":306,"keywords":312,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":113},"100528995","influenza--covid-19-obstetric-and-perinatal-epidemiology-study-in-india-100528995","NCT06168019","Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India","Influenza & COVID-19 Obstetric and Perinatal Epidemiology (ICOPE) Study in India","ICOPE","Inclusion Criteria:\n\nWomen aged 18 to 50 years registering for antenatal care (ANC) at Government Medical College Hospital (GMC) Nagpur, India\n\n* Estimated Gestational Age at registration \\\u003C14 weeks based on ultrasound report at the baseline study visit;\n* Intends to receive pregnancy, labor and delivery and neonatal care at GMC;\n* Plans to live within the city limits of Nagpur throughout their pregnancy and labor and delivery to facilitate access to GMC for evaluation of ILI and COVID-19 symptoms;\n* Willing to be contacted two times per week by call or text for ILI\u002F COVID-19 symptom screening and return to GMC for evaluation and an NP swab\u002Fevaluation if symptoms are reported;\n* Willing to take temperature with the provided digital thermometer, and maintain a symptom diary after training;\n* Willing to provide information on pregnancy and neonatal outcomes if care occurs outside GMC;\n* Willing to permit venous blood draws on at least 4 timepoints --1) Baseline study visit, 2)28-34 weeks, 3) 37 weeks - prior to delivery and 4) after delivery;\n* Willing to permit blood draws if hospitalized at GMC for COVID-19 infection;\n* Willing to consent to participate in the study\n\nExclusion Criteria:\n\n* Anyone who is deemed to have limited decision-making capacity as defined by Boston University IRB i.e. Substantial impairment of cognitive functions (e.g. attention, comprehension, memory, and intellect), or conditions that might affect their cognitive functions.\n* Anyone who is deemed to have limited capacity to consent as defined by Boston University Institutional Review Board (IRB) i.e. The ability to provide legally effective consent to enroll in a research study (AAHRPP definition).","FEMALE","50 Years",{"count":304,"type":20},10000,"This study will be conducted as a prospective cohort study, enrolling all eligible women in their first trimester of pregnancy during a baseline visit during week 6-13 of pregnancy at Government Medical College Hospital, Nagpur. The Hospital provides primary, secondary, and tertiary care and the obstetric department delivers about 10,000 babies a year. The hypothesis is that co-infection of other respiratory viruses (ORV), particularly COVID-19 and Influenza increases the risk of adverse pregnancy outcomes in mothers and babies and could address the current standard of care in India to not vaccinate pregnant women during pregnancy, by either encouraging vaccination against both viruses before planning a pregnancy or during pregnancy based on global data supporting the safety of this strategy.",[307,130,308,309,310,311],"Influenza","SARS-COV-2 Infection","Other Respiratory Viruses","Perinatal Morbidity","Infant Morbidity",[313,314,315,316,317],"Pregnant women","Government Medical College Hospital, Nagpur, India","Covid-19 vaccination","Antenatal care","Postpartum","2025-11-26",{"date":320,"type":37},"2025-11-28",{"date":322,"type":37},"2023-12-26",{"date":324,"type":20},"2028-06",{"name":112,"class":44},{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":16,"sex":17,"minAge":333,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":125,"phases":337,"briefSummary":338,"conditions":339,"keywords":340,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":113},"100578410","phase-1-a-phase-12a-randomized-study-of-a-t-follicular-helper-tfh-targeting-genetic-vaccine-strategy-designed-to-induce-broad-durable-immune-responses-100578410","NCT06810934","A Phase 1\u002F2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses","CONTENDER","Inclusion Criteria:\n\n1. Individuals 40 - 64 years of age\n2. Received at least two doses of a COVID-19 mRNA vaccine (Moderna or Pfizer) \\> 120 days before study entry\n3. Nasal SARS-CoV-2 negative by molecular (polymerase chain reaction, PCR) testing at screening\n4. The following laboratory criteria must be met at screening:\n\n   1. Total white blood cell (WBC) count \\> 3500 cells\u002Fmm3\n   2. Absolute neutrophil count (ANC) \\> 1500 cells\u002Fmm3\n   3. Hemoglobin \\> 13.5 g\u002FdL if male sex and \\> 12.0 g\u002FdL if female sex\n   4. Platelet count \\> 140,000\u002FuL\n   5. Estimated creatinine clearance (CrCl) \\> 50 mL\u002Fmin by Cockroft-Gault equation\n   6. Total bilirubin ≤ 1.1x upper limit of normal (ULN)\n   7. Aspartate aminotransferase (AST) ≤ 1.3x ULN\n   8. Alanine aminotransferase (ALT) ≤ 1.3x ULN\n5. Individuals of reproductive potential must have a negative serum or urine beta-human chorionic gonadotropin (ß-HCG) test at screening and within 48 hours prior to entry.\n\n   Reproductive potential is defined as:\n   * Participants who have reached menarche\n   * Participants who have not been post-menopausal for at least 12 consecutive months with follicle-stimulating hormone (FSH) ≥40 IU\u002FmL or 24 consecutive months if an FSH is not available\n   * Participants who have not undergone surgical contraception (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or bilateral salpingectomy) NOTE: Participants who have undergone bilateral tubal ligation within the 24 weeks prior to screening are considered to be of reproductive potential and, if participating in sexual activity that could lead to pregnancy, contraception is required as per 5.2.2 exclusion criterion 2.\n6. Able and willing to provide informed consent\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria are met:\n\n1. Pregnant or breastfeeding\n2. For participants capable of becoming pregnant and engaging in sexual activity that can lead to pregnancy, unwillingness to use contraception during participation in the study. For participants capable of becoming pregnant, two of the following forms of contraception are required through 30 days following administration of study intervention, one of which must be a barrier method:\n\n   1. Condoms (male or female) with or without a spermicidal agent\n   2. Diaphragm or cervical cap with spermicide\n   3. Intrauterine device (IUD)\n   4. Hormone-based contraceptive such as oral birth control pills\n3. Known close contact with anyone with confirmed SARS-CoV-2 infection (defined as positive SARS-CoV-2 nucleic acid or antigen testing by laboratory-based or home self-test) within 2 weeks prior to expected study entry\n4. Plan to receive a non-study SARS-CoV-2 vaccine within 8 weeks after study entry\n5. HIV infection\n6. Hepatitis B core antibody or hepatitis B surface antigen positive at screening\n7. Current active hepatitis C. Participants must be hepatitis C virus (HCV) antibody negative or have evidence of cleared HCV infection. If the participant is HCV antibody positive or indeterminate, an unquantifiable HCV RNA result (below lower limit of quantification, either target detected or target not detected) within 42 days prior to study entry is required. Those who are currently receiving HCV antiviral therapy or those who have received HCV treatment in the last 3 months prior to study entry will be excluded.\n8. History of cirrhotic liver disease\n9. History of thrombosis with thrombocytopenia syndrome (TTS), immune thrombocytopenia, thromboembolic events, capillary leak syndrome, other thrombotic disease or known increased risk of thrombosis due to genetic disorders or malignancy\n10. History of or active autoimmune disease that has required systemic immunosuppressive or immunomodulatory therapy\n11. History of myocarditis, pericarditis, or myopericarditis\n12. Potential myocarditis or pericarditis identified at screening, defined as high-sensitivity troponin I (hsTnI) \\> ULN or 12-lead ECG compatible with pericarditis WITH compatible symptoms (regardless of troponin I level) at screening\n13. History of Guillain-Barré syndrome\n14. History of coagulopathy or bleeding disorder considered a contraindication to intramuscular injection or phlebotomy\n15. Symptomatic acute or chronic illness requiring ongoing medical or surgical care, including requirement for new medications, in the past 3 months. Transient illnesses or injuries that are resolved prior to screening are not exclusionary. Minor adjustments in stable therapy for chronic conditions such as hypertension are not exclusionary. Use of over-the-counter medications for any acute or chronic illness is also not exclusionary.\n16. Serious medical or psychiatric illness that, in the opinion of the site investigator, would interfere with the ability to adhere to study requirements or to give informed consent\n17. Treatment with systemic immunosuppressive or immunomodulatory drugs, and\u002For exposure to any immunosuppressive\u002Fimmunomodulatory drug in the 30 days prior to study entry (e.g. corticosteroid therapy equal to or exceeding a dose of 20 mg\u002Fday of prednisone for more than 10 days, interleukins, interferons, methotrexate, rituximab, and cancer chemotherapy). Use of topical, inhaled, intra-articular, or nasal steroid use is not exclusionary.\n18. Active malignancy or history of malignancy within the 4 years prior to study entry. Non-melanoma skin cancers (such as basal or squamous cell skin cancers) and non-invasive cervical or anal intraepithelial lesions are not exclusionary.\n19. History of solid organ or hematopoietic stem cell transplantation\n20. History of primary immunodeficiency disorder\n21. Ongoing complications or morbidity associated with prior diagnoses of malignancies requiring continued medical or surgical intervention. Chronic stable complications or morbidity not requiring new medications or other medical or surgical intervention in the past 3 months are not exclusionary.\n22. Administration or planned administration of blood products or licensed non-SARS-CoV-2 vaccines \\<14 days prior to or within 14 days after study entry\n23. Receipt of any antibody-based therapy (investigational or approved) for prophylaxis or treatment of COVID-19 in the preceding 6 months\n24. Receipt of immunoglobulin therapy in the year prior to study entry or scheduled or anticipated immunoglobulin administration during the study period.\n25. Prior receipt of any non-mRNA SARS-CoV-2 vaccine\n26. Receipt of any SARS-CoV-2 vaccination in the 120 days prior to study entry\n27. Documented SARS-CoV-2 infection in the 120 days prior to study entry\n28. History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention (medications requiring a prescription or surgical intervention) after receipt of a vaccine or intervention that includes one or more of the same components contained in the study product\n29. Have participated in an interventional clinical study within 28 days prior to screening (based on medical history interview) or plans to do so while participating in this study\n30. Any clinical concerns as determined by the investigator that might affect the potential participant's safety in the study.","40 Years","64 Years",{"count":336,"type":20},80,[209,255],"The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64. The CoTend-s3BXBB vaccine includes a component called \"s3\", which was designed to improve the body's response to the vaccine. CoTend-BXBB is the same vaccine without s3.\n\nThe main questions the study aims to answer are: 1) Is the investigational vaccine safe? 2) Does \"s3\" lead to bigger, broader, and longer-lasting responses to the vaccine?\n\n5 different doses of the vaccines will be studied. Participants will receive a single dose of either CoTend-s3BXBB, CoTend-BXBB, or placebo. Participants will be monitored for side effects. Saliva, nasal, and blood samples will be collected and immune responses to the vaccine will be measured.",[130,25],[130,28,341,342,343,344,345,346,347,348,349,350,158],"Vaccine","Adjuvant","Virus","RNA Virus Infections","Prevention","Immunogenicity","Immunity","Viral infection","Coronavirus Infection","Infection","2025-10-29",{"date":353,"type":37},"2025-10-31",{"date":355,"type":37},"2025-10-21",{"date":357,"type":20},"2029-10",{"name":359,"class":44},"Kara Chew",{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":17,"minAge":122,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":125,"phases":370,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":45},"100608100","phase-2-safety-and-effectiveness-of-a-remdesivir-treatment-to-prevent-severe-covid-19-in-kidney-transplant-patients-100608100","NCT07197164","Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients","Safety and Efficacy of 10-day Course of Remdesivir to Prevent Severe COVID-19 in Asymptomatic or Paucisymptomatic SARS-COV-2-positive Kidney Transplant Recipients: a Single-arm Proof-of-concept Interventional Trial","COVIDKIDNEY","Inclusion Criteria:\n\n1. At least 18 years-old\n2. Patients with end-stage kidney disease that are included on the local kidney transplant waiting list who get an offer of a compatible organ and, subsequently, have a transplant procedure scheduled in the next 24 (+\u002F-) 12 hours, or patients with end-stage kidney disease that are planned to receive a non-cadaveric donor kidney transplant on the following 5 days.\n3. Have a positive SARS-CoV-2 nasopharyngeal PCR or RAT within 5 days prior to transplant surgery.\n4. Have previously received at least three SARS-CoV-2 vaccine doses, with a minimum time elapsed of 3 months since the last dose received.\n5. Are asymptomatic or have mild acute COVID-19 symptoms during the previous 5 days (headache, sore throat, cough, chest pain, nausea, diarrhea, fatigue, loss of smell or taste, myalgia) excluding fever in the previous 48 hours (\\>38ºC) or shortness of breath.\n6. Post-menopausal or fertile females (females who are not surgically sterile or postmenopausal defined as amenorrhea for \\>12 months) that agree to avoid pregnancy during the study. If sexually active fe-male; using highly effective contraceptive methods (hormonal contraception, intra-uterine device (IUD), or anatomical sterility in self or partner\\*) while on study treatment. All female volunteers must be willing to undergo urine pregnancy tests at time of enrollment.\n7. Having understood the information provided and capable of giving consent to participate in this trial by signing the Informed Consent document.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women, at time of enrollment\n2. Patients requiring supplementary oxygen at baseline or diagnosed with severe COPD or pulmonary fibrosis.\n3. Patients having any of the following at the screening period: i) O2 saturation below 94% on room air; ii) respiratory frequency of \\> 30bpm; or iii) Xray showing new-onset pulmonary infiltrates suggesting COVID-19 pneumonia.\n4. Patients having fever (\\>38ºC) in the last 48 hours or shortness of breath in the previous 5 days.\n5. Previous history of hypersensitivity, documented allergy or contraindications to receive remdesivir.\n6. ABO incompatible kidney transplant\n7. Desensitization therapy indicated as induction therapy for high immunological risk transplant with Donor Specific HLA Antibodies (DSA)\n8. Participants who receive different types of induction immunosuppression other than the standard induction protocols with lymphocyte- depleting agents (thymoglobulin or basiliximab).\n9. Active liver disease with AST or ALT \\>3 ULN, Total bilirubin ≥2 × ULN (for Gilbert's syndrome, direct bilirubin \\>ULN is exclusionary) within the past 3 months, or liver function impairment with Class B or C per Child Pugh classification.\n10. Suspected or confirmed concurrent active respiratory infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.\n11. Any comorbidity requiring hospitalization and\u002For surgery within 7 days prior to study entry, or that is considered life threatening within 30 days prior to study entry, as determined by the investigator.\n12. Prior participation in this trial.\n13. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.",{"count":369,"type":20},15,[255],"Since the start of the COVID-19 pandemic, the approach to solid organ transplantation has evolved. Transplants using organs (excluding lungs) from COVID-19-positive donors have shown short-term safety, but there is limited data on recipients who are SARS-CoV-2 positive. Currently, kidney transplants in such recipients are delayed until symptoms resolve and a negative PCR is preferred, despite the risks of prolonged dialysis and increased cold ischemia time.\n\nRecent data from the Omicron era suggest that early antiviral treatment may reduce complications. Immunosuppressive therapy might even help mitigate severe inflammatory responses. The proposed study aims to show that kidney transplantation can be safely performed in asymptomatic or mildly symptomatic COVID-19-positive recipients who begin antiviral treatment (remdesivir) within 24 hours before transplant and continue for 10 days. This could reduce waiting times and improve outcomes.\n\nRemdesivir is an antiviral safe for use in patients with low kidney function, including those on dialysis or post-transplant, with minimal side effects. The hypothesis is that this treatment strategy can prevent progression to severe COVID-19 and allow safe transplantation",[373,374,60],"COVID - 19","Renal Transplant","2025-09-26",{"date":377,"type":37},"2025-09-29",{"date":379,"type":37},"2025-09-01",{"date":381,"type":20},"2027-02-28",{"name":383,"class":44},"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":16,"sex":17,"minAge":122,"maxAge":88,"enrollmentInfo":391,"targetDuration":4,"studyType":125,"phases":393,"briefSummary":394,"conditions":395,"keywords":396,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":407,"leadSponsor":409,"locationsCount":113},"100487925","phase-1-next-generation-t-cell-vaccine-against-coronavirus-disease-covid-19-100487925","NCT05633446","Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)","A Phase I-II, Blinded, Randomized, Placebo-controlled Study of a T Cell Priming Next-generation Vaccine Against Coronavirus Disease in Healthy Adults","Inclusion Criteria:\n\n1. Healthy volunteers aged 18 to 75 years on the day of inclusion\n2. Participant signed informed consent\n3. Residing in Philippines.\n4. A participant can be included providing COVID-19 polymerase chain reaction (PCR) test is negative at screening.\n5. A participant can be included providing, the participant haven't received any vaccination against COVID-19 in the past, or if the participant had already received any of the following licensed vaccines against COVID-19: Oxford\u002FAstraZeneca; Pfizer\u002FBioNTech; Moderna; or J\\&J\u002FJanssen, with the participants last dose received at least 6 months prior the inclusion in this trial.\n\nExclusion Criteria:\n\n1. Participant is pregnant, lactating, or of childbearing potential\n2. Participation in the 6 months preceding the first trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure\n3. Receipt of any vaccination against COVID-19 less than 6 months prior to participation in study.\n4. Receipt of any vaccine in the three months preceding the first trial vaccination or planned receipt of any vaccine in the 6 months following last trial vaccination.\n5. Positive SARS-CoV-2 test in the 4 weeks preceding the first trial vaccination\n6. Receipt of immunoglobulins, blood, or blood-derived products in the past 3 months\n7. Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy\n8. Self-reported or documented seropositivity for human immunodeficiency virus (HIV), hepatitis B natural infection (HBcAb positive serology), or hepatitis C\n9. Known systemic hypersensitivity to any of the vaccine components (e.g. gold), or history of a life-threatening reaction to vaccines or to a vaccine containing any of the same substances\n10. Current alcohol abuse or drug addiction (reported or suspected)\n11. Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion\n12. Thrombocytopenia or any coagulation disorder\n13. Identified as an Investigator or employee of the Investigator or study centre with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study (i.e. in the employment of the clinical trial sites).\n14. Refusal to be informed if relevant results concerning the participant's health are revealed",{"count":392,"type":20},110,[209,255],"The study aims to investigate the safety and immunogenicity of one dose vs two doses of a T-cell priming next-generation vaccine against Coronavirus disease.",[131,25,130],[131,28,130,397,398,399,400,401,402],"T-cell priming","COVID vaccine","Nanoparticle","T cell","Cellular immunity","T-cell vaccine","2025-02-21",{"date":405,"type":37},"2025-02-24",{"date":379,"type":20},{"date":408,"type":20},"2026-12-01",{"name":410,"class":244},"Gylden Pharma Ltd",{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":17,"minAge":122,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":125,"phases":421,"briefSummary":422,"conditions":423,"keywords":427,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":45},"100468805","olfactory-training-as-a-treatment-for-olfactory-dysfunction-post-covid-19-100468805","NCT05384561","Olfactory Training As a Treatment for Olfactory Dysfunction Post COVID-19","L'entraînement Olfactif Comme Traitement De La Dysfonction Olfactive Post COVID-19","OTTODC19","Inclusion Criteria:\n\n* Patient diagnosed positive for COVID-19 with persistent olfactory dysfunction\n* Willing and able to provide written informed consent\n* Understand and read the French language\n* Have an internet connection and a working email address\n\nExclusion Criteria:\n\n* Anosmia and hyposmia pre-covid-19\n* Be known chronic rhinosinusitis with or without nasal polyposis\n* Have received radiotherapy or chemotherapy for Head and Neck Tumors\n* Have a diagnosis of Alzheimer's, Parkinson's, multiple sclerosis or any other neurodegenerative disease 5. Have a brain tumor or ENT diagnosis 6. History of naso-sinus surgery; 7. History of traumatic brain injury",{"count":420,"type":20},70,[127],"Olfactory dysfunction is a defining symptom of COVID-19 infection. Studies have demonstrated improved olfaction in patients with post infectious olfactory dysfunction after an olfactory training (OT). The aim of this study is to assess the clinical outcomes of olfactory training (12 weeks) therapy in the treatment of persistent olfactory dysfunctions after COVID-19. Specially, we aim to compare the effectiveness of two different olfactory training (different odors).\n\nA group will train themselves with 4 scents (rose, orange, clove and eucalyptus) and another group with 4 different scents (cheese, coffee, strawberries and lemon). Olfaction sensory evaluation will be performed by using different olfaction tests (Sniffin' Sticks and UPSIT) and complete questionnaires to assess olfactory perception and particularly parosmia and phantosmia.",[424,130,425,426,25],"Hyposmia","Parosmia","Anosmia",[428,429,430],"Olfactory training","Chemosensory impairments","Persistent smell impairment","2024-12-11",{"date":433,"type":37},"2024-12-17",{"date":435,"type":37},"2022-05-31",{"date":437,"type":20},"2025-09",{"name":439,"class":44},"Université du Québec à Trois-Rivières",{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":449,"conditions":450,"keywords":452,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":45},"100400480","sars-cov-2-infection-in-kidney-transplant-recipients-a-brazilian-multicenter-study-100400480","NCT04494776","SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Infection (COVID-19) in Kidney Transplant Recipients: a Brazilian Multicenter Study","Inclusion Criteria:\n\n1. Kidney transplant recipients, which may be multi-organ recipients, transplanted in any follow-up period;\n2. Positive diagnostic test for COVID-19 (detection of viral load, test for detection of antigens or tests for detection of antibodies);\n3. Outpatient or hospital management;\n4. Adults and children.\n\nExclusion Criteria:\n\n\\-",{"count":448,"type":20},500,"COVID-19 is the pandemic disease caused by the SARS-CoV-2 coronavirus. It is a highly contagious viral disease, the condition of which main clinical symptoms are characterized by fever and respiratory symptoms. Evidence indicates to worse outcomes in patients with pre-existing diseases, such as diabetes, arterial hypertension, heart disease, pneumopathies, chronic kidney disease, and immunodeficiencies. Recipients of kidney transplants make prolonged use of immunosuppressive drugs to inhibit the acquired immune response, notably the activity of lymphocytes. Due to this potential to modulate the immune and inflammatory response, it is speculated that the clinical and laboratory condition of COVID-19 in these patients is atypical. Preliminary evidence suggests worse outcomes of COVID-19 in immunosuppressed patients, as carriers of cancer. However, information on kidney transplant recipients is insufficient. So far, only reports of the case are available in the literature with different clinical presentations and outcomes. The aim of this study is, therefore, to characterize the demographics, clinical and laboratory conditions, and the outcomes of COVID-19 in kidney transplant recipients in a national multicenter cohort.",[25,451],"Kidney Transplant Infection",[25,451,453],"Kidney Transplant","2024-11-07",{"date":456,"type":37},"2024-11-08",{"date":458,"type":37},"2020-05-21",{"date":460,"type":20},"2025-04-02",{"name":462,"class":44},"Helio Tedesco Silva Junior",{"id":464,"slug":465,"hasResults":11,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":16,"sex":17,"minAge":122,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":473,"conditions":474,"keywords":477,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":113},"100549544","sars-cov-2-specific-antibody-responses-and-impact-for-covid-19-disease-in-ethiopia-100549544","NCT06435403","SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethiopia","SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Health Care Worker and Community Members From Ethiopian Related to Natural SARS CoV-2 Infection and COVID-19 Vaccination","CoVICIS","Inclusion criteria:\n\n1. Adults, 18 years of above\n2. Provision of oral as well as written informed consent\n3. Available estimation of the period or the time-point when SARS-CoV-2 infection occurred (e.g. confirmed or highly suspected COVID-19 disease, SARS-CoV-2 anti-nucleocapsid seroconversion) (only applicable for participants included in group 1 and 2).\n4. Employed\u002Fworking in hospital (medical doctors, nurses\u002Fmidwives, students, auxiliary personnel such as cleaner, runner, social worker) for HCW\n5. Willingness to provide blood samples by venipuncture for serology and immunological characterization\n6. Willingness to provide health information, report medical events and to performed SARS-CoV-2 diagnostics (swabs for PCR) in the case of suspected COVID-19 disease\n\nExclusion criteria:\n\n1. Prisoners\n2. Mentally disturbed persons\n3. Persons for whom study participation will induce an unacceptable risk or burden as judged by the investigator (e.g. seriously sick persons)",{"count":472,"type":20},1000,"In this study we aim to characterize SARS CoV-2 strain specific immune response (SARS-CoV-2 Spike IgG) in health care workers and general populations at the Jimma Medical Center and the St. Paul Hospital in Addis Ababa in association to clinical immune protection and Covid-19 disease. Participants, stratified by SARS-CoV-2 infection and vaccination status, will be followed at 3-month intervals for a maximum of 2 years. Prevalence, incidence, and dynamics of SARS-CoV-2 specific antibodies as well as clinical assessments especially related to COVID-19 breakthrough disease in previously exposed\u002Fvaccinated participants will be performed. From a subset of selected participant blood sample, more in depth immunological analysis will be performed that include virus culture-based neutralization assays, antibody avidity assays, SARS-CoV-2 specific antibody epitope recognition using peptide arrays, and T-cell immunity assays (IGRA).\n\nWe also plan to analyze and model cost-effectiveness considerations related to adapted COVID-19 vaccine strategies, specifically if SARS-CoV-2 the costs for routine sero-diagnosis in high SARS-CoV-2 prevalent population prior to vaccination will impact the decision to vaccinate (no vaccination for low-risk populations or reduced vaccine dosing) and is cost-efficient. The study is largely exploratory, providing deeper insights in SARS-CoV-2 specific immune responses and interaction with SARS-CoV-2 viral variants.",[60,475,476],"COVID-19 Breakthrough","COVID-19 Recurrent",[130,478,479,480,28],"Seroepidemiologic Studies","Longitudinal Studies","Ethiopia \u002F epidemiology","2024-07-08",{"date":483,"type":37},"2024-07-09",{"date":485,"type":37},"2022-11-10",{"date":487,"type":20},"2025-02-28",{"name":489,"class":44},"Michael Hoelscher",{"id":491,"slug":492,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":11,"sex":17,"minAge":122,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":125,"phases":499,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":4},"100527174","collection-of-additional-biological-samples-from-potentially-covid-19-patients-for-monitoring-of-biological-parameters-carried-out-as-part-of-the-routine-100527174","NCT06144333","Collection of Additional Biological Samples From Potentially COVID-19 Patients for Monitoring of Biological Parameters Carried Out as Part of the Routine","CEB Covid-19","Inclusion Criteria:\n\n* Patient over 18 years old\n* Patient coming for a biological analysis as part of the care for prevention, screening or monitoring of the pathogen target\n* Patient able to understand the information note and give a free and informed consent, on paper or digital media\n* Clinical patients:\n\n  * Control cases (all comers or ambulatory)\n  * Known positive for the pathology concerned\n  * Patient hospitalized for the pathology concerned\n* Pregnant or breastfeeding patient\n* Dialysis patient\n\nExclusion Criteria:\n\n* Patient already included in a research protocol\n* Patient having received medication or treatment experimental or investigational during the last four weeks before collection\n* Patient subject to a legal protection measure\n* Patient affiliated with state medical aid (AME)\n* Patient not affiliated to the compulsory Social Security system\n* Refusal or inability to provide signed informed consent\n* According to the investigator, the patient is not eligible for inclusion in the study",{"count":498,"type":20},7500,[127],"Patients infected with SARS-CoV-2 can present with a wide range of manifestations clinical conditions, ranging from no symptoms to serious or chronic illness. The current gold standard test for the diagnosis of COVID-19 is based on a molecular test of reverse transcription polymerase chain reaction (RT-PCR), aimed at detecting the RNA of the virus in respiratory samples such as nasopharyngeal swabs or aspirates bronchial, other methods such as antigen tests and serological detection tests IgM and IgG in response to COVID-19 viral infection, can be used for the purposes of screening in the general population.\n\nIn this context of variety of existing tests, it is important to monitor the biological parameters related to COVID-19 pathology by tracking the accuracy, specificity and sensitivity of these tests in current clinical practice.\n\nThis research is a collection of additional biological samples with minimal impact on the intake usual care of the patients concerned, for the monitoring of biological parameters carried out in routine on several reagent kits used for screening for the SARS-CoV-2 virus, in terms of sensitivity, specificity, positive and negative predictive values, for the implementation of indicators quality monitoring of these kits.",[60],"2024-04-12",{"date":504,"type":37},"2024-04-15",{"date":506,"type":20},"2024-12-23",{"date":508,"type":20},"2026-11-23",{"name":510,"class":44},"CerbaXpert",{"id":512,"slug":513,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":11,"sex":17,"minAge":122,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":520,"conditions":521,"keywords":522,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":45},"100507835","covid-19-early-detection-of-worsening-by-voice-and-respiratory-pattern-characteristics-100507835","NCT05892549","COVID-19: Early Detection of Worsening by Voice and Respiratory Pattern Characteristics","COVOICE","Inclusion Criteria:\n\n* French speaking\n* Affiliated to a social security system\n* Owning a mobile phone capable of accessing the COVOICE application\n\nExclusion Criteria:\n\n* Incapable adults\n* People deprived of their liberty\n* People under administrative or judicial supervision\n* Patients intubated or hospitalized in intensive care unit",{"count":519,"type":20},1188,"In some clinical forms of COVID-19, an uncontrolled hyper-inflammatory reaction known as a \"cytokine storm\" appears abruptly, around day 7, and is associated with rapid respiratory deterioration, requiring hospitalization in an intensive care unit (ICU).\n\nAt present, although risk factors for this severe form have been described, there are no validated criteria for determining which individual patients will develop this aggravation.\n\nThe study of respiratory sounds (amplitude, frequency, ...) has made it possible in other respiratory pathologies (e.g., chronic obstructive pulmonary disease) to predict exacerbations several days in advance.\n\nHaving a predictive respiratory pattern for worsening in COVID-19 would make it possible to anticipate the need for intensive care hospital beds, by means of a tool easily available on a mobile phone.",[157,130],[523],"Voice","2023-06-13",{"date":526,"type":37},"2023-06-15",{"date":528,"type":37},"2023-06-12",{"date":530,"type":20},"2026-07",{"name":532,"class":44},"Direction Centrale du Service de Santé des Armées","SARS CoV-2 Infection"]